4.5 Review

Axial spondyloarthritis: concept, construct, classification and implications for therapy

Journal

NATURE REVIEWS RHEUMATOLOGY
Volume 17, Issue 2, Pages 109-118

Publisher

NATURE RESEARCH
DOI: 10.1038/s41584-020-00552-4

Keywords

-

Categories

Ask authors/readers for more resources

The concept of axial spondyloarthritis (axSpA) has evolved significantly since the definition of ankylosing spondylitis in 1984, from solely erosions in the sacroiliac joints to a spectrum of disease with or without visible changes on plain radiographs. The use of MRI has greatly impacted the diagnosis and classification of axSpA, yet there is still controversy surrounding the specificity of current classification criteria.
The axial spondyloarthritis (axSpA) disease concept has undergone substantial change from when the entity ankylosing spondylitis was defined by the modified New York criteria in 1984. Developments in imaging, therapy and genetics have all contributed to changing the concept of axSpA from one of erosions in the sacroiliac joints to a spectrum of disease with and without changes evident on plain radiographs. Changes to the previously held concept and construct of the disease have also necessitated new classification criteria. The use of MRI, primarily of the sacroiliac joints, has substantially altered the diagnosis and differential diagnosis of axSpA. Many in the axSpA community believe that the current classification criteria lack specificity, and the CLASSIC study is underway to examine this area. Although much about the evolving axSpA disease concept is universally agreed, there remains disagreement about operationalizing aspects of it, such as the requirement for the objective demonstration of axial inflammation for the classification of axSpA. New imaging technologies, biomarkers and genetics data will probably necessitate ongoing revision of axSpA classification criteria. Advances in our knowledge of the biology of axSpA will settle some differences in opinion as to how the disease concept is applied to the classification and diagnosis of patients. In this Review, the authors examine how the definition and description of axial spondyloarthritis (axSpA) has evolved, most notably with the introduction of the concept of non-radiographic axSpA, and discuss the implications of these changes for diagnosis, classification and therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Rheumatology

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Arnaud and Devilliers

Pedro M. Machado, Martin Schaefer, Anja Strangfeld, Laure Gossec, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F. Mateus, Loreto Carmona, Kimme L. Hyrich, Philip C. Robinson, Jinoos Yazdany

ANNALS OF THE RHEUMATIC DISEASES (2023)

Letter Rheumatology

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Mulhearn et al

Martin Schaefer, Anja Strangfeld, Kimme L. Hyrich, Loreto Carmona, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F. Mateus, Laure Gossec, Philip C. Robinson, Jinoos Yazdany, Pedro M. Machado

ANNALS OF THE RHEUMATIC DISEASES (2023)

Letter Rheumatology

Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Rosenbaum et al

Kimme L. Hyrich, Martin Schaefer, Anja Strangfeld, Loreto Carmona, Laure Gossec, Elsa F. Mateus, Saskia Lawson-Tovey, Milena Gianfrancesco, Philip C. Robinson, Jinoos Yazdany, Pedro M. Machado

ANNALS OF THE RHEUMATIC DISEASES (2023)

Letter Rheumatology

Response to: Correspondence on Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis by Sparks et al

Jeffrey A. Sparks, Zachary S. Wallace, Andrea M. Seet, Philip C. Robinson, Pedro M. Machado, Jinoos Yazdany

ANNALS OF THE RHEUMATIC DISEASES (2023)

Review Rheumatology

Examining the Characteristics of Colchicine-Induced Myelosuppression in Clinical Cases: A Systematic Review

Bernice L. Sim, Beatrice Z. Sim, Matthew Tunbridge, David F. L. Liew, Philip C. Robinson

Summary: This systematic review identified 30 studies involving 47 patients with myelosuppression caused by colchicine. Most patients had comorbidities, such as renal impairment, and were taking CYP3A4 or P-gp inhibitors. The severity of myelosuppression varied, ranging from moderate anemia to severe thrombocytopenia, neutropenia, and leukopenia.

JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

COVID-19 vaccine hesitancy in inflammatory arthritis patients: serial surveys from a large longitudinal national Australian cohort

Christopher McMaster, David F. L. Liew, Susan Lester, Adam Rischin, Rachel J. Black, Vibhasha Chand, Ashley Fletcher, Marissa N. Lassere, Lyn March, Philip C. Robinson, Rachelle Buchbinder, Catherine L. Hill

Summary: This study aimed to determine the COVID-19 vaccine hesitancy rates among inflammatory arthritis patients and identify factors associated with changing vaccine hesitancy over time. The findings showed that beliefs about medication harm and overuse before the pandemic were associated with COVID-19 vaccine hesitancy. Furthermore, individuals who did not seek vaccine information from healthcare professionals were more likely to develop vaccine hesitancy during the pandemic.

RHEUMATOLOGY (2023)

Article Rheumatology

Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance

Manuel F. Ugarte-Gil, Graciela S. Alarcon, Andrea M. Seet, Zara Izadi, Anna D. Montgomery, Ali Duarte-Garcia, Emily L. Gilbert, Maria O. Valenzuela-Almada, Leanna Wise, Jeffrey A. Sparks, Tiffany Y. -T. Hsu, Kristin M. D'Silva, Naomi J. Patel, Emily Sirotich, Jean W. Liew, Jonathan S. Hausmann, Paul Sufka, Rebecca Grainger, Suleman Bhana, Zachary Wallace, Lindsay Jacobsohn, Anja Strangfeld, Elsa F. Mateus, Kimme L. Hyrich, Laure Gossec, Loreto Carmona, Saskia Lawson-Tovey, Lianne Kearsley-Fleet, Martin Schaefer, Pedro M. Machado, Philip C. Robinson, Milena Gianfrancesco, Jinoos Yazdany

Summary: A study on individuals with SLE in the US found that Black and Hispanic patients had higher odds of experiencing more severe COVID-19 outcomes compared to White patients, which may be attributed to socioeconomic and health disparities.

ARTHRITIS CARE & RESEARCH (2023)

Editorial Material Rheumatology

Ankylosing spondylitis: History, epidemiology, and HLA-B27

Muhammad Asim Khan, Su-Boon Yong, James Cheng-Chung Wei

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2023)

Article Rheumatology

The International Map of Axial Spondyloarthritis Survey: A US Patient Perspective on Diagnosis and Burden of Disease

Marina Magrey, Jessica A. A. Walsh, Sandra Flierl, Richard A. A. Howard, Renato C. C. Calheiros, David Wei, Muhammad A. A. Khan

Summary: This study investigated the impact of axial spondyloarthritis (axSpA) on work activity, day-to-day function, mental health, relationships, and quality of life among US patients. The results showed that most patients experienced a significant delay in the diagnosis of axSpA, with a longer delay in women compared to men. Patients also reported active disease, psychological distress, and impaired function. The study highlighted the disease burden and limitations in daily activities associated with axSpA.

ACR OPEN RHEUMATOLOGY (2023)

Article Public, Environmental & Occupational Health

Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors

Victor Yang, Tue W. Kragstrup, Christopher McMaster, Pankti Reid, Namrata Singh, Stine R. Haysen, Philip C. Robinson, David F. L. Liew

Summary: Janus kinase inhibitors (JAKi) have shown great potential as immune-modulating therapies for chronic inflammatory diseases. However, concerns about cardiovascular and cancer risks have arisen from recent studies, particularly in patients with rheumatoid arthritis and existing cardiovascular risk. While this risk has not been fully demonstrated in other patient populations, it has led to a re-evaluation of the use of JAKi in various contexts. Clinicians must carefully consider these risks and other factors when considering JAKi as a treatment option for their patients.

DRUG SAFETY (2023)

Editorial Material Rheumatology

The challenge of new classification criteria for axial spondyloarthritis

Muhammad Asim Khan, Su-Boon Yong, Sjef van Der Linden

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2023)

Article Rheumatology

Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries

Pedro M. Machado, Martin Schaefer, Satveer K. Mahil, Jean Liew, Laure Gossec, Nick Dand, Alexander Pfeil, Anja Strangfeld, Anne Constanze Regierer, Bruno Fautrel, Carla Gimena Alonso, Carla G. S. Saad, Christopher E. M. Griffiths, Claudia Lomater, Corinne Miceli-Richard, Daniel Wendling, Deshire Alpizar Rodriguez, Dieter Wiek, Elsa F. Mateus, Emily Sirotich, Enrique R. Soriano, Francinne Machado Ribeiro, Felipe Omura, Frederico Rajao Martins, Helena Santos, Jonathan Dau, Jonathan N. Barker, Jonathan Hausmann, Kimme L. Hyrich, Lianne Gensler, Ligia Silva, Lindsay Jacobsohn, Loreto Carmona, Marcelo M. Pinheiro, Marcos David Zelaya, Maria de los Angeles Severina, Mark Yates, Maureen Dubreuil, Monique Gore-Massy, Nicoletta Romeo, Nigil Haroon, Paul Sufka, Rebecca Grainger, Rebecca Hasseli, Saskia Lawson-Tovey, Suleman Bhana, Thao Pham, Tor Olofsson, Wilson Bautista-Molano, Zachary S. Wallace, Zenas Z. N. Yiu, Jinoos Yazdany, Philip C. Robinson, Catherine H. Smith

Summary: This study investigated factors associated with severe COVID-19 in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis. The study found that age, sex, comorbidities, disease activity, and glucocorticoid use were associated with the severity of COVID-19. Additionally, later pandemic time periods, psoriasis, and the use of TNFi, IL17i, and IL-23i/IL-12+23i were associated with a reduced risk of severe COVID-19.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

HLA-B*27 and Ankylosing Spondylitis: 50 Years of Insights and Discoveries

Muhammad A. Khan

Summary: This article reviews the 50th anniversary of the discovery of the strong association between HLA-B*27 and AS, summarizes the recent findings, and highlights the presence of clonally expanded CD8+ T cells in AS patients who carry the HLA-B*27 gene. The study also reveals the distinct affinity of the T-cell receptors alpha and beta chain motifs for specific peptides, leading to an autoimmune response and the onset of the disease.

CURRENT RHEUMATOLOGY REPORTS (2023)

Letter Rheumatology

Response to: Correspondence on Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis by Sparks et al

Zachary S. Wallace, Jeffrey A. Sparks, Philip C. Robinson, Pedro M. Machado, Jinoos Yazdany

ANNALS OF THE RHEUMATIC DISEASES (2023)

No Data Available